AbbVie Outpaces Pfizer in Growth Trajectory and Dividend Sustainability

AbbVie (NYSE: ABBV) is emerging as a stronger growth play in the pharmaceutical sector, successfully navigating the 'patent cliff' that continues to challenge Pfizer (NYSE: PFE). While Pfizer's stock has seen a year-to-date increase of over 10% compared to AbbVie's 7% decline, fundamental financial metrics suggest a divergence in their long-term trajectories. AbbVie's diversification strategy is evident in the performance of Skyrizi and Rinvoq, which generated combined sales of $25.9 billion in 2025—surpassing the peak yearly sales of the former top-seller Humira. In contrast, Pfizer's Comirnaty sales plummeted 35% last year to $4.4 billion, and its leading revenue driver, Eliquis, which saw $7.9 billion in 2025 sales, is expected to face generic competition in the U.S. by 2028. Dividend sustainability also favors AbbVie, which maintains a 65% payout ratio and a 54-year history of increases. Pfizer's 6.3% yield is undercut by an unsustainable 107% payout ratio. Although Pfizer has raised its dividend for 16 consecutive years, including a recent bump to $0.43 per share, its ability to increase payouts is limited by current cash from operations. Looking ahead to 2026, the financial outlooks diverge further. AbbVie expects revenue to grow 9.5% to approximately $67 billion, with adjusted EPS projected to rise significantly to between $14.37 and $14.57. Conversely, Pfizer's 2026 guidance suggests a revenue decline of 2.5% at the midpoint to a range of $59.5 billion to $62.5 billion, with adjusted EPS expected to fall 9% at the midpoint to between $2.80 and $3.